Applications of Irsogladine Maleate in Industrial Manufacturing

Irsogladine Maleate, as a highly specialized pharmaceutical intermediate, serves distinct functions in various regulated downstream production environments. Our manufacturing process ensures both traceability and consistency, supporting partners in sectors with strict compliance expectations. Below, we present real application scenarios based on verified industry practices.

1. Active Pharmaceutical Ingredient (API) Manufacturing for Gastroprotective Drugs

Global pharmaceutical companies incorporate this material as a primary intermediate during the synthesis of finished products aimed at managing gastric mucosal protection. Manufacturers select this compound specifically for its favorable pharmacokinetic and safety profiles documented in international pharmacopoeias. Processing facilities require precise integration measures ensuring both regulatory compliance and product batch integrity for human therapeutics.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice for Active Pharmaceutical Ingredients
• US FDA cGMP Title 21 CFR Part 210/211
• Japanese Pharmacopoeia (JP)
• European Pharmacopoeia (Ph. Eur.)

Typical usage ratio

• Integrated as a core ingredient at an assay of 99.0-101.0% on the dried basis in final API formulations; specific batch loading adjusted according to pharmacopoeial monograph requirements and targeted final yield.

Downstream process integration

• Introduced during the API condensation and crystallization stage immediately after primary synthesis, purified through recrystallization, and subjected to micronization prior to granulation for tableting or encapsulation.

Final product types

• Gastroprotective drug tablets
• Oral capsules for ulcer management
• Stomach mucosal protective prescription medicines

2. Formulation of Combination Prescription Drugs (Co-formulation with PPIs)

Combination drug product manufacturers employ this ingredient in co-tableting and co-granulation with proton pump inhibitors (PPIs) to enhance clinical outcomes for patients requiring long-term acid suppression. Formulation scientists account for chemical compatibility and regulatory documentation to ensure stability and uniformity throughout the release profile required by local regulatory submissions.

Industry compliance standards

• China Pharmacopoeia (ChP)
• WHO GMP for Finished Pharmaceutical Products
• Relevant local health authority registrations (e.g., NMPA - China, CDSCO - India)

Typical usage ratio

• Blended at 5-15% w/w of total formulation mass depending on finished dosage strength and fixed-dose combination guidelines; precise ratio determined via compatibility and bioequivalence studies.

Downstream process integration

• Added during high-shear granulation as part of the pre-lubrication blend, followed by tableting or capsule filling; in-process controls monitor blend uniformity and dissolution properties.

Final product types

• Fixed-dose combination tablets (e.g., PPI + mucosal protective agent)
• Multilayered oral solid dosage forms
• Blister-packed prescription medications

3. Clinical Trial Sample Preparation for Early-Stage Drug Development

Contract research organizations (CROs) and pharmaceutical innovators require consistent and high-purity batches of this compound for pre-clinical and clinical trial support. Quality assurance protocols guide handling in trial batch production, where reference material traceability and audit trail completeness remain paramount.

Industry compliance standards

• OECD Principles of Good Laboratory Practice (GLP)
• FDA IND submission guidance (Investigational New Drug)
• ISO/IEC 17025 laboratory accreditation

Typical usage ratio

• Titrated based on trial arm design from microdoses to standard clinical dosing concentrations (commonly ranging from 1 mg to 30 mg per unit, depending on protocol phase); solution and suspension forms formulated per protocol requirements.

Downstream process integration

• Weighing and dispensing performed under controlled environmental conditions for sample kit assembly, followed by encapsulation, liquid fill, or direct tableting used as the basis for human or animal trial interventions.

Final product types

• Clinical trial solid dosage reference samples
• Trial-grade oral solution units
• Pre-formulated stability reference packs

4. Benchmark Standard Production for Pharmacopoeial and Laboratory Use

Analytical laboratories and pharmacopoeial testing centers depend on traceable, high-purity material meeting defined specifications for calibration, system suitability, and validation studies. Consistent physical and chemical characteristics are critical for standard curve preparation and reference sample certification.

Industry compliance standards

• ISO 17034:2016 General Requirements for the Competence of Reference Material Producers
• USP Reference Standard requirements
• Ph. Eur. Analytical Reference Material guidelines

Typical usage ratio

• Utilized at laboratory scale for system calibration, typically in microgram to milligram quantities depending on assay type and validation needs; working standard solutions standardized at 0.1-1 mg/mL.

Downstream process integration

• Dispersed in analytical solvents and subjected to chromatographic or spectrophotometric analysis; incorporated into instrument calibration runs and quality control check batches for pharmaceutical laboratories.

Final product types

• Certified reference standards
• Calibration solutions for HPLC/LC-MS
• Quality control standard kits